JP2019052115A - 医薬組成物 - Google Patents
医薬組成物 Download PDFInfo
- Publication number
- JP2019052115A JP2019052115A JP2017177926A JP2017177926A JP2019052115A JP 2019052115 A JP2019052115 A JP 2019052115A JP 2017177926 A JP2017177926 A JP 2017177926A JP 2017177926 A JP2017177926 A JP 2017177926A JP 2019052115 A JP2019052115 A JP 2019052115A
- Authority
- JP
- Japan
- Prior art keywords
- adrenergic receptor
- receptor antagonist
- cerebral
- administered
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 34
- 238000003892 spreading Methods 0.000 claims abstract description 42
- 230000007480 spreading Effects 0.000 claims abstract description 42
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 40
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 40
- 230000001054 cortical effect Effects 0.000 claims abstract description 33
- 208000014644 Brain disease Diseases 0.000 claims abstract description 25
- 239000000674 adrenergic antagonist Substances 0.000 claims description 59
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 31
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 31
- 230000002490 cerebral effect Effects 0.000 claims description 26
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 claims description 24
- 230000001629 suppression Effects 0.000 claims description 21
- 230000005764 inhibitory process Effects 0.000 claims description 12
- 208000018152 Cerebral disease Diseases 0.000 claims description 11
- 230000028161 membrane depolarization Effects 0.000 abstract description 5
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 abstract 2
- 239000002464 receptor antagonist Substances 0.000 abstract 2
- 229940044551 receptor antagonist Drugs 0.000 abstract 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 63
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 26
- 238000000034 method Methods 0.000 description 26
- 239000001103 potassium chloride Substances 0.000 description 25
- 235000011164 potassium chloride Nutrition 0.000 description 25
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 22
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 20
- 229910001414 potassium ion Inorganic materials 0.000 description 20
- 206010061216 Infarction Diseases 0.000 description 15
- 229960003002 atipamezole Drugs 0.000 description 15
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 15
- 230000007574 infarction Effects 0.000 description 15
- 229960001289 prazosin Drugs 0.000 description 15
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 15
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000011591 potassium Substances 0.000 description 12
- 229910052700 potassium Inorganic materials 0.000 description 12
- 208000007536 Thrombosis Diseases 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 229960003712 propranolol Drugs 0.000 description 11
- -1 AIO-8507L Chemical compound 0.000 description 9
- 210000003710 cerebral cortex Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 229910001424 calcium ion Inorganic materials 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108060003345 Adrenergic Receptor Proteins 0.000 description 5
- 102000017910 Adrenergic receptor Human genes 0.000 description 5
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 230000002123 temporal effect Effects 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 230000008035 nerve activity Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- JWEXHQAEWHKGCW-BIISKSHESA-N (R,S,S,S)-nebivolol hydrochloride Chemical compound Cl.C1CC2=CC(F)=CC=C2O[C@H]1[C@@H](O)CNC[C@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 JWEXHQAEWHKGCW-BIISKSHESA-N 0.000 description 2
- ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960003588 bevantolol Drugs 0.000 description 2
- HXLAFSUPPDYFEO-UHFFFAOYSA-N bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 229960001389 doxazosin Drugs 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- WMDSZGFJQKSLLH-RBBKRZOGSA-N landiolol Chemical compound O1C(C)(C)OC[C@H]1COC(=O)CCC(C=C1)=CC=C1OC[C@@H](O)CNCCNC(=O)N1CCOCC1 WMDSZGFJQKSLLH-RBBKRZOGSA-N 0.000 description 2
- 229950005241 landiolol Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960001300 metoprolol tartrate Drugs 0.000 description 2
- GHACVBCUANDNID-VQIMIIECSA-N n-[4-[(1s)-1-hydroxy-2-[[(2r)-1-oxo-3,4-dihydro-2h-naphthalen-2-yl]methylamino]ethyl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1[C@H](O)CNC[C@@H]1C(=O)C2=CC=CC=C2CC1 GHACVBCUANDNID-VQIMIIECSA-N 0.000 description 2
- 229940068174 nebivolol hydrochloride Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000000977 primary visual cortex Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960003198 tamsulosin hydrochloride Drugs 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 229960001130 urapidil Drugs 0.000 description 2
- SHHCJPKACHSWFP-NMXGMQNUSA-N (1s,3as,3bs,5ar,9ar,9bs,11as)-n-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;5-[(2r)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1.O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F SHHCJPKACHSWFP-NMXGMQNUSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SZSMNSNVWDKMMN-LVEZLNDCSA-N (E)-but-2-enedioic acid 3-[[2-(4-hydroxy-5-methyl-2-propan-2-ylphenoxy)ethyl-methylamino]methyl]-4-methoxy-2,5,6-trimethylphenol Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.COc1c(C)c(C)c(O)c(C)c1CN(C)CCOc1cc(C)c(O)cc1C(C)C SZSMNSNVWDKMMN-LVEZLNDCSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- CHDPSNLJFOQTRK-LMOVPXPDSA-N (S)-betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OC[C@@H](O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-LMOVPXPDSA-N 0.000 description 1
- RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 description 1
- DGNIOISQRMXGCK-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-[2-[3-[2-(2-ethyl-6-methoxyphenoxy)ethylamino]propyl]-3,4,5-trimethoxyphenyl]acetonitrile Chemical compound OC(=O)\C=C\C(O)=O.CCC1=CC=CC(OC)=C1OCCNCCCC1=C(CC#N)C=C(OC)C(OC)=C1OC DGNIOISQRMXGCK-WLHGVMLRSA-N 0.000 description 1
- FFKRVMYEUOOFBT-UHFFFAOYSA-N 1-(2-ethoxy-2-pyridin-3-ylethyl)-4-(2-methoxyphenyl)piperazine Chemical compound C=1C=CN=CC=1C(OCC)CN(CC1)CCN1C1=CC=CC=C1OC FFKRVMYEUOOFBT-UHFFFAOYSA-N 0.000 description 1
- YLPWNPUPMQZIKN-UHFFFAOYSA-N 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-(2-methoxy-6-propan-2-ylphenoxy)ethanone;hydrochloride Chemical compound Cl.N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)COC1=C(OC)C=CC=C1C(C)C YLPWNPUPMQZIKN-UHFFFAOYSA-N 0.000 description 1
- FBOUYBDGKBSUES-KEKNWZKVSA-N 1-azabicyclo[2.2.2]octan-3-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(OC2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-KEKNWZKVSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- WJDFSAOMSJHHCG-UHFFFAOYSA-N 2-[3-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)propyl]pyridazin-3-one;hydrochloride Chemical compound Cl.O=C1C=CC=NN1CCCNCC1OC2=CC=CC=C2OC1 WJDFSAOMSJHHCG-UHFFFAOYSA-N 0.000 description 1
- NNPHPGSVPQWUHP-UHFFFAOYSA-N 2-[3-[4-(5-chloro-2-methoxyphenyl)piperazin-1-yl]propylamino]pyrimidine-4-carboxamide Chemical compound COC1=CC=C(Cl)C=C1N1CCN(CCCNC=2N=C(C=CN=2)C(N)=O)CC1 NNPHPGSVPQWUHP-UHFFFAOYSA-N 0.000 description 1
- FJNRJBQUOQLUNQ-CYBMUJFWSA-N 2-[3-[[(3r)-2,3-dihydro-1,4-benzodioxin-3-yl]methylamino]propyl]pyridazin-3-one Chemical compound O=C1C=CC=NN1CCCNC[C@H]1OC2=CC=CC=C2OC1 FJNRJBQUOQLUNQ-CYBMUJFWSA-N 0.000 description 1
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
- NPNDIKQZGVCHMQ-UHFFFAOYSA-N 3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-1h-quinazoline-2,4-dione;hydrochloride Chemical compound Cl.COC1=CC=CC=C1N1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 NPNDIKQZGVCHMQ-UHFFFAOYSA-N 0.000 description 1
- GYGUWRJKLIJBQP-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(1,3-benzodioxol-5-yl)carbamate;hydrochloride Chemical compound Cl.C1=C2OCOC2=CC(NC(=O)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 GYGUWRJKLIJBQP-UHFFFAOYSA-N 0.000 description 1
- COCJIISORPXDPN-UHFFFAOYSA-N 3-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-one Chemical compound COc1ccccc1N1CCN(CC2CNc3n2c(=O)nc2ccccc32)CC1 COCJIISORPXDPN-UHFFFAOYSA-N 0.000 description 1
- QADWEQVSNYLMRN-UHFFFAOYSA-N 3-o-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl] 5-o-methyl 2,6-dimethyl-4-(3-nitrophenyl)-2,5-dihydropyridine-3,5-dicarboxylate Chemical compound C=1C=CC([N+]([O-])=O)=CC=1C=1C(C(=O)OC)C(C)=NC(C)C=1C(=O)OCCCN(CC1)CCN1C1=CC=CC=C1OC QADWEQVSNYLMRN-UHFFFAOYSA-N 0.000 description 1
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 1
- PMIAIKWRXUGRQG-QGZVFWFLSA-N 4-[(3r)-3-[2-amino-4-(4-fluorophenyl)-1,3-thiazol-5-yl]pyrrolidin-1-yl]-1-(4-fluorophenyl)butan-1-one Chemical compound C([C@H](C1)C2=C(N=C(S2)N)C=2C=CC(F)=CC=2)CN1CCCC(=O)C1=CC=C(F)C=C1 PMIAIKWRXUGRQG-QGZVFWFLSA-N 0.000 description 1
- QAMJKGFUHUBPQN-UHFFFAOYSA-N 4-[3-[4-[3-[4-(2-methoxyphenyl)piperazin-1-yl]-1-(4-methylphenyl)propoxy]benzoyl]indol-1-yl]butanoic acid Chemical compound COC1=CC=CC=C1N1CCN(CCC(OC=2C=CC(=CC=2)C(=O)C=2C3=CC=CC=C3N(CCCC(O)=O)C=2)C=2C=CC(C)=CC=2)CC1 QAMJKGFUHUBPQN-UHFFFAOYSA-N 0.000 description 1
- YOIOINQCJZQHPS-YDBXVIRUSA-N 5-[[[(1s,2s,3s)-2-hydroxy-3-phenoxycyclopentyl]amino]methyl]-2-methyl-6,7-dihydro-5h-1-benzothiophen-4-one;hydrochloride Chemical compound Cl.O([C@H]1CC[C@@H]([C@@H]1O)NCC1CCC2=C(C1=O)C=C(S2)C)C1=CC=CC=C1 YOIOINQCJZQHPS-YDBXVIRUSA-N 0.000 description 1
- UUWABVCZFXKHSU-UHFFFAOYSA-N 5-chloro-4-[2-[[3-(2-chlorophenoxy)-2-hydroxypropyl]amino]ethylamino]-1h-pyridazin-6-one Chemical compound C=1C=CC=C(Cl)C=1OCC(O)CNCCNC=1C=NNC(=O)C=1Cl UUWABVCZFXKHSU-UHFFFAOYSA-N 0.000 description 1
- IPSYNNODBHPDFB-UHFFFAOYSA-N 7-[3-[4-(4-fluorobenzoyl)piperidin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCN(CC1)CCC1C(=O)C1=CC=C(F)C=C1 IPSYNNODBHPDFB-UHFFFAOYSA-N 0.000 description 1
- RUELBIYEEYFIQA-UHFFFAOYSA-N 7-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCCN(CC1)CCC1C(=O)C1=CC=C(F)C=C1 RUELBIYEEYFIQA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 108010003032 CHIR 2279 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
- VKJHTUVLJYWAEY-UHFFFAOYSA-N Celiprolol hydrochloride Chemical compound Cl.CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 VKJHTUVLJYWAEY-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- YARKMNAWFIMDKV-UHFFFAOYSA-N Epanolol Chemical compound C=1C=CC=C(C#N)C=1OCC(O)CNCCNC(=O)CC1=CC=C(O)C=C1 YARKMNAWFIMDKV-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZDZXCYHMVFLGMT-BTJKTKAUSA-N Monatepil maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1N1CCN(CCCC(=O)NC2C3=CC=CC=C3SCC3=CC=CC=C32)CC1 ZDZXCYHMVFLGMT-BTJKTKAUSA-N 0.000 description 1
- HRRBJVNMSRJFHQ-UHFFFAOYSA-N Naftopidil Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C3=CC=CC=C3C=CC=2)CC1 HRRBJVNMSRJFHQ-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108010067973 Valinomycin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960003830 acebutolol hydrochloride Drugs 0.000 description 1
- KTUFKADDDORSSI-UHFFFAOYSA-N acebutolol hydrochloride Chemical compound Cl.CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 KTUFKADDDORSSI-UHFFFAOYSA-N 0.000 description 1
- VRYMTAVOXVTQEF-UHFFFAOYSA-N acetic acid [4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] ester Chemical compound CC(C)C1=CC(OC(C)=O)=C(C)C=C1OCCN(C)C VRYMTAVOXVTQEF-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229960003103 alfuzosin hydrochloride Drugs 0.000 description 1
- YTNKWDJILNVLGX-UHFFFAOYSA-N alfuzosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 YTNKWDJILNVLGX-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229950010351 amosulalol Drugs 0.000 description 1
- LVEXHFZHOIWIIP-UHFFFAOYSA-N amosulalol Chemical compound COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 LVEXHFZHOIWIIP-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229950005503 arnolol Drugs 0.000 description 1
- LAWLHMWODZUZJH-UHFFFAOYSA-N arnolol Chemical compound COCCC1=CC=C(OCC(O)C(C)(C)N)C=C1 LAWLHMWODZUZJH-UHFFFAOYSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- IUGQFMIATSVYLK-UHFFFAOYSA-N benzyl 2-(4-hydroxyphenyl)acetate Chemical compound C1=CC(O)=CC=C1CC(=O)OCC1=CC=CC=C1 IUGQFMIATSVYLK-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960005400 bisoprolol fumarate Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960003612 bunazosin hydrochloride Drugs 0.000 description 1
- 229950008581 bunitrolol Drugs 0.000 description 1
- VCVQSRCYSKKPBA-UHFFFAOYSA-N bunitrolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1C#N VCVQSRCYSKKPBA-UHFFFAOYSA-N 0.000 description 1
- WAHFGTZTVZRLEY-UHFFFAOYSA-N butanedioic acid;piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone Chemical compound OC(=O)CCC(O)=O.CC(C)OC1=CC=CC=C1N1CCN(CC=2C=C(C=CC=2)C(=O)N2CCCCC2)CC1 WAHFGTZTVZRLEY-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 229960002320 celiprolol Drugs 0.000 description 1
- 229960000384 celiprolol hydrochloride Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229950003205 cetamolol Drugs 0.000 description 1
- UWCBNAVPISMFJZ-UHFFFAOYSA-N cetamolol Chemical compound CNC(=O)COC1=CC=CC=C1OCC(O)CNC(C)(C)C UWCBNAVPISMFJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- FCFNRCROJUBPLU-UHFFFAOYSA-N compound M126 Natural products CC(C)C1NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC1=O FCFNRCROJUBPLU-UHFFFAOYSA-N 0.000 description 1
- 238000007428 craniotomy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WQVZLXWQESQGIF-WJKBNZMCSA-N dilevalol hydrochloride Chemical compound Cl.C([C@@H](C)NC[C@H](O)C=1C=C(C(O)=CC=1)C(N)=O)CC1=CC=CC=C1 WQVZLXWQESQGIF-WJKBNZMCSA-N 0.000 description 1
- GQJFGCIETONRNJ-UHFFFAOYSA-N dimethyl 4-[2-[4-[(2-hydroxy-3-phenoxypropyl)amino]butoxy]-5-nitrophenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC([N+]([O-])=O)=CC=C1OCCCCNCC(O)COC1=CC=CC=C1 GQJFGCIETONRNJ-UHFFFAOYSA-N 0.000 description 1
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229940033643 dutasteride / tamsulosin Drugs 0.000 description 1
- 229950005111 ecastolol Drugs 0.000 description 1
- 229960002711 epanolol Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- QZWUQVSQIFFFKY-UHFFFAOYSA-N ersentilide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OCC(O)CNCCOC1=CC=C(N2C=NC=C2)C=C1 QZWUQVSQIFFFKY-UHFFFAOYSA-N 0.000 description 1
- GNZBRPIPARUNNB-UHFFFAOYSA-N ethyl 4-[3-(tert-butylamino)-2-hydroxypropoxy]-3-methoxybenzoate Chemical compound CCOC(=O)C1=CC=C(OCC(O)CNC(C)(C)C)C(OC)=C1 GNZBRPIPARUNNB-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229950006834 fluprofylline Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229960002056 indoramin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000236 levobetaxolol hydrochloride Drugs 0.000 description 1
- JDYWZVJXSMADHP-UHFFFAOYSA-N lidanserin Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OCCCN(CC1)CCC1C(=O)C1=CC=C(F)C=C1 JDYWZVJXSMADHP-UHFFFAOYSA-N 0.000 description 1
- 229950003713 lidanserin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- YEOTYALSMRNXLJ-UHFFFAOYSA-N metazosin Chemical compound C1CN(C(=O)C(C)OC)CCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 YEOTYALSMRNXLJ-UHFFFAOYSA-N 0.000 description 1
- JQTJGLURUUNKCA-UHFFFAOYSA-N methyl 2-amino-4-[2-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butylsulfinyl]phenyl]-6-methyl-5-nitro-1,4-dihydropyridine-3-carboxylate Chemical compound COC(=O)C1=C(N)NC(C)=C([N+]([O-])=O)C1C1=CC=CC=C1S(=O)CCCCN1CCN(C=2C(=CC=CC=2)OC)CC1 JQTJGLURUUNKCA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960003509 moxisylyte Drugs 0.000 description 1
- OLYXPBZBZBVRGD-UHFFFAOYSA-N n-[2-(4-amino-6,7-dimethoxy-5-pyridin-2-ylquinazolin-2-yl)-3,4-dihydro-1h-isoquinolin-5-yl]methanesulfonamide Chemical compound COC=1C(OC)=CC2=NC(N3CC4=C(C(=CC=C4)NS(C)(=O)=O)CC3)=NC(N)=C2C=1C1=CC=CC=N1 OLYXPBZBZBVRGD-UHFFFAOYSA-N 0.000 description 1
- JAOKSQLUELFTBL-UHFFFAOYSA-N n-[2-[(2-amino-2-oxoethyl)-(2-phenylethyl)amino]-2-oxoethyl]-2-[2-(4-hydroxyphenyl)ethylamino]-n-(4-phenylphenyl)acetamide Chemical compound C=1C=C(O)C=CC=1CCNCC(=O)N(C=1C=CC(=CC=1)C=1C=CC=CC=1)CC(=O)N(CC(=O)N)CCC1=CC=CC=C1 JAOKSQLUELFTBL-UHFFFAOYSA-N 0.000 description 1
- DUCNHKDCVVSJLG-UHFFFAOYSA-N n-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-methyl-4-oxo-2-phenylchromene-8-carboxamide Chemical compound COC1=CC=CC=C1N1CCN(CCCNC(=O)C=2C3=C(C(C(C)=C(O3)C=3C=CC=CC=3)=O)C=CC=2)CC1 DUCNHKDCVVSJLG-UHFFFAOYSA-N 0.000 description 1
- CGUIWXDBHIFQJV-UHFFFAOYSA-N n-[4-[3-[2-(3,4-dimethoxyphenyl)ethylamino]-2-hydroxypropoxy]-3-(1,2-oxazol-5-yl)phenyl]butanamide Chemical compound C=1C=NOC=1C1=CC(NC(=O)CCC)=CC=C1OCC(O)CNCCC1=CC=C(OC)C(OC)=C1 CGUIWXDBHIFQJV-UHFFFAOYSA-N 0.000 description 1
- 229950005705 naftopidil Drugs 0.000 description 1
- IOSMPEJNAQZKJT-UHFFFAOYSA-N neldazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N1CCN(C(=O)CC(C)O)CC1 IOSMPEJNAQZKJT-UHFFFAOYSA-N 0.000 description 1
- 229950004512 neldazosin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229950000754 nipradilol Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229950006281 perbufylline Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 239000003308 potassium ionophore Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002386 prazosin hydrochloride Drugs 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229950008920 ridazolol Drugs 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- RARHXUAUPNYAJF-QSYGGRRVSA-N samidorphan l-malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.N1([C@@H]2CC3=CC=C(C(=C3[C@@]3([C@]2(CCC(=O)C3)O)CC1)O)C(=O)N)CC1CC1 RARHXUAUPNYAJF-QSYGGRRVSA-N 0.000 description 1
- MUAHMQUPOQGKOQ-UHFFFAOYSA-N savoxepin Chemical compound C12=CC(C#N)=CC=C2OC2=CC=CC=C2C(CC2)=C1CCN2CC1CCCC1 MUAHMQUPOQGKOQ-UHFFFAOYSA-N 0.000 description 1
- 229950005727 savoxepin Drugs 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960001368 solifenacin succinate Drugs 0.000 description 1
- 210000004092 somatosensory cortex Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229950005035 taprizosin Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001909 terazosin hydrochloride Drugs 0.000 description 1
- VCVWXKKWDOJNIT-ZOMKSWQUSA-N tesofensine Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@@H]2COCC)=CC=C(Cl)C(Cl)=C1 VCVWXKKWDOJNIT-ZOMKSWQUSA-N 0.000 description 1
- 229950009970 tesofensine Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229950001695 upidosin Drugs 0.000 description 1
- FCFNRCROJUBPLU-DNDCDFAISA-N valinomycin Chemical compound CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O FCFNRCROJUBPLU-DNDCDFAISA-N 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
本実施形態に係る大脳皮質拡延性抑制を伴う脳疾患を治療または予防することに用いるための医薬組成物(以下、大脳皮質拡延性抑制を伴う脳疾患の治療用医薬組成物ともいう)は、α1アドレナリン受容体拮抗薬またはβアドレナリン受容体拮抗薬の少なくともいずれかを含み、必要に応じて、更にその他の成分を含有する。
ここで、大脳皮質拡延性抑制を伴う脳疾患は、脳梗塞、急性の虚血、外傷性脳損傷、片頭痛、てんかん発作(痙攣)などである。
本実施形態では一例として脳皮質拡延性抑制を伴う脳疾患は、脳梗塞であり、本実施形態に係る脳梗塞を治療または予防することに用いるための医薬組成物(以下、脳梗塞の治療用医薬組成物ともいう)は、α1アドレナリン受容体拮抗薬またはβアドレナリン受容体拮抗薬の少なくともいずれかを含み、必要に応じて、更にその他の成分を含有する。
α1アドレナリン受容体拮抗薬(遮断薬)としては、α1アドレナリン受容体を拮抗(または遮断)することができれば、特に制限はなく、α1アドレナリン受容体を選択的に拮抗(または遮断)する薬でもよいし、α1アドレナリン受容体だけでなく他の受容体を拮抗(または遮断)する薬であってもよく、目的に応じて適宜選択することができる。
βアドレナリン受容体拮抗薬としては、βアドレナリン受容体を拮抗することができれば、特に制限はなく、βアドレナリン受容体を選択的に拮抗(または遮断)する薬でもよいし、βアドレナリン受容体だけでなく他の受容体を拮抗(または遮断)する薬であってもよく、目的に応じて適宜選択することができる。
上記その他の成分としては、特に制限はなく、薬理学上許容される担体の中から投与方法や剤型などに応じて適宜選択することができる。
例えば、上記大脳皮質拡延性抑制を伴う脳疾患(例えば、脳梗塞)の治療用組成物が、経口固形剤として用いられる場合、乳糖、白糖、塩化ナトリウム、ブドウ糖、デンプン、炭酸カルシウム、カオリン、微結晶セルロース、珪酸等の賦形剤;水、エタノール、プロパノール、単シロップ、ブドウ糖液、デンプン液、ゼラチン液、カルボキシメチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルスターチ、メチルセルロース、エチルセルロース、シェラック、リン酸カルシウム、ポリビニルピロリドン等の結合剤;乾燥デンプン、アルギン酸ナトリウム、カンテン末、炭酸水素ナトリウム、炭酸カルシウム、ラウリル硫酸ナトリウム、ステアリン酸モノグリセリド、乳糖等の崩壊剤;精製タルク、ステアリン酸塩、ホウ砂、ポリエチレングリコール等の滑沢剤;酸化チタン、酸化鉄等の着色剤;白糖、橙皮、クエン酸、酒石酸等の矯味/矯臭剤などが挙げられる。
上記大脳皮質拡延性抑制を伴う脳疾患(例えば、脳梗塞)の治療用医薬品組成物の投与時期としては、特に制限はなく、目的に応じて適宜選択することができる。上記脳疾患(例えば、脳梗塞)発症後において脳損傷が広がる前に投与されることが治療効果を高めるうえで好ましい。従って、発症後12時間以内、好ましくは6時間以内、4時間以内がさらに好ましく、脳疾患(例えば、脳梗塞)発症前または脳梗塞発症後2時間以内がより好ましい。なお、発症から長い時間を経過して投与する場合には、α1アドレナリン受容体拮抗薬およびβアドレナリン受容体拮抗薬は適宜、当業者において選択し得るものである。また、上記脳疾患(例えば、脳梗塞)発症前に投与される場合は、本発明の治療用医薬品組成物は上記脳疾患の予防用医薬品組成物として用いることができる。
上記大脳皮質拡延性抑制を伴う脳疾患(例えば、脳梗塞)の治療用医薬品組成物の投与方法としては、特に制限はなく、当該脳疾患(例えば、脳梗塞)の治療用医薬品組成物における、上記α1アドレナリン受容体拮抗薬や上記βアドレナリン受容体拮抗薬の種類や含有量などに応じて適宜選択することができ、例えば、経口投与法、注射(例えば静脈注射、髄注など)による方法、吸入による方法などが挙げられる。
上記大脳皮質拡延性抑制を伴う脳疾患(例えば、脳梗塞)の治療用医薬品組成物の投与量としても、特に制限はなく、投与対象個体の年齢、体重、体質、症状、他の成分を有効成分とする医薬の投与の有無など、様々な要因を考慮して適宜選択することができる。
選択することができる。
投与対象となる動物種としては、特に制限はなく、目的に応じて適宜選択すること
ができ、例えば、ヒト、サル、ブタ、ウシ、ヒツジ、ヤギ、イヌ、ネコ、マウス、ラット、トリなどが挙げられるが、これらの中でもヒトに好適に用いられる。
<実験動物>
カルシウムイオンイメージングには、最近発明者らのグループが開発した遺伝子改変マウスラインG7NG817(非特許文献5参照)を用いた。この遺伝子改変マウスラインG7NG817は、カルシウムセンサG-CaMP7が主に皮質のアストロサイトに発現しており、より少量、神経細胞にも発現している。
図1を参照して、本願実施例の大脳皮質拡延性抑制を伴う脳疾患モデルマウスの作製方法を説明する。図1は、CSDに伴うカルシウム波の典型例である。ウレタン麻酔下で、300mMの塩化カリウム(KCl)を小さな開頭穴から脳の視覚野に局所投与することによって大脳皮質拡延性抑制を伴う脳疾患モデルマウスを作製した。
マウスは、ヘッドフレームに固定することによって、脳固定器のステージに固定され、蛍光実体顕微鏡(MZ10F, Leica)に下に配置された。GFP3フィルターセット(励起光:470 ± 20 nm、出射光:525 ± 25 nm、Leica)がEL6000光源(Leica)とともに使用された。画像は、HC Image ソフトウェア(浜松フォトニクス)を使用することによって、ORCA-Flash 2.0 CMOSカメラ(浜松フォトニクス)によって取得された。HC Image ソフトウェアは、イメージング中に頭蓋骨だけを照らすためにシャッターユニットも制御する。画像は、512 × 512画素、16ビットの解像度、及び10Hzで取得された。
局所電場電位(local field potential)計測がELC-03XS増幅器(NPI electronic).を用いて実施された。ガラスのマイクロピペット(先端径が2μm、1B150F-4, World Precision Instruments)がHEPES-ACSF(pH 7.4)で満たされて、ヘッドステージのプリアンプとともに電極ホルダーに配置された。その後、このヘッドステージは、遠隔制御のマイクロマニピュレータ(Sensapix)に固定された。実体顕微鏡下で、ガラスのマイクロピペットは、一次視覚野に30度で軟膜から250μmまで挿入された。計測セッションは、誘発応答の安定のために、電極が挿入されてから1から2時間後に開始された。信号は、2000倍に増幅され且つ0.1 Hzから3kHzの周波数帯にフィルターされた後、LabVIEWベースのデータ取得システムによって20kHzでデジタル化されて、ハードディスクに保存された。この局所電場電位(local field potential)計測は、室内灯の下で実施された。
細胞外カリウム濃度を計測するために、ピペットプラー(Sutter)を用いて、10μmより小さい先端径のダブルバレルのガラスピペット(A-M SYSTEMS, INC., 607000)からイオン感受性マイクロ電極が作製された。ピペットは、小さな容器得で200℃で1時間、ジメチルシラン(dimethylsilane)を蒸発させることによって、シラン処理された。一方の電極の先端はバリノマイシン(valinomycin)ベースのカリウムイオン交換レジン(カリウムのイオノフォア、フロントロード)で満たされ、続いて150 mMの塩化カリウムで満たされる。他方の電極の先端は、150 mMの塩化ナトリウムで満たされ、LFP計測のために基準電極として用いられる。
図1には、塩化カリウム(KCl)を時刻0で局所投与することによって生じるCSDを視覚化するために、無傷の頭蓋骨を通してカルシウムイオンイメージングを行った結果の一例が示されている。塩化カリウム(KCl)を矢印の位置に投与後を、カルシウムイオン濃度が急上昇し、塩化カリウム(KCl)投与後1分以内において、同側の皮質全体において、このカルシウムイオン濃度上昇領域が伝搬する。
<実験動物>
細胞外カリウムイオン濃度計測及びTTC染色には、C57BL/6マウスを用いた。
カルシウムイオンイメージングには、最近発明者らのグループが開発した遺伝子改変マウスラインG7NG817(非特許文献5参照)を用いた。この遺伝子改変マウスラインG7NG817は、カルシウムセンサG-CaMP7が主に皮質のアストロサイトに発現しており、より少量、神経細胞にも発現している。
図4は、光血栓法による限局性脳梗塞を起こす手順を示す図である。図4Aに示すように、ローズベンガルを110mg/kgで腹腔内投与する。投与後5分後に、緑色の光を15分間、ターゲット領域(直径2mm、一次視覚野)に照射する。これにより、図4Bに示すように、血中内のローズベンガルが光によって硬化し、図4Bの矢印に示すように血栓ができる。但し、図5の実験では、緑色の光の照射時間は10分である。
光血栓法により血栓を作ってから24時間後、マウスは麻酔下でよく冷えたPBSで環流され、環流後に脳を取り出され、取り出された脳を2%の2,3,5-triphenyltetrazolium chloride(TTC)で37℃で15分間、浸す。
図5は、遺伝子改変マウスラインG7NG817のマウスで光血栓法により血栓を作ったときの、伝搬するカルシウムイオン波のタイムラプスイメージング結果の一例である。図5に示すように、遺伝子改変マウスラインG7NG817のマウスに、光血栓法により血栓を作ると、710秒後からカルシウム波が発生した。このように、光血栓法により血栓を作るとCSDが発生する。
また、α1アドレナリン受容体拮抗薬またはβアドレナリン受容体拮抗薬の少なくともいずれかを含む医薬組成物は、脳梗塞だけでなく、原理を同じくする大脳皮質拡延性抑制を伴う脳疾患に対しても治療効果または予防効果を有することが明らかであり、α1アドレナリン受容体拮抗薬またはβアドレナリン受容体拮抗薬の少なくともいずれかを含む医薬組成物は、大脳皮質拡延性抑制を伴う脳疾患に対しても治療用または予防用に用いることができる。
Claims (2)
- α1アドレナリン受容体拮抗薬またはβアドレナリン受容体拮抗薬のうち少なくともいずれかを含む、大脳皮質拡延性抑制を伴う脳疾患を治療または予防することに用いるための医薬組成物。
- 前記大脳皮質拡延性抑制を伴う脳疾患は、脳梗塞である
請求項1に記載の医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017177926A JP2019052115A (ja) | 2017-09-15 | 2017-09-15 | 医薬組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017177926A JP2019052115A (ja) | 2017-09-15 | 2017-09-15 | 医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019052115A true JP2019052115A (ja) | 2019-04-04 |
Family
ID=66014321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017177926A Pending JP2019052115A (ja) | 2017-09-15 | 2017-09-15 | 医薬組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2019052115A (ja) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60142922A (ja) * | 1983-12-28 | 1985-07-29 | Fujisawa Pharmaceut Co Ltd | 脳梗塞治療剤 |
JPH0256426A (ja) * | 1988-08-19 | 1990-02-26 | Sumitomo Pharmaceut Co Ltd | 虚血性脳障害処置剤 |
WO2005030202A1 (en) * | 2003-09-26 | 2005-04-07 | Novartis Ag | Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders |
JP2005508922A (ja) * | 2001-10-04 | 2005-04-07 | ユーランド ファーマシューティカルズ リミテッド | プロプラノロールの時限徐放性多粒子剤型 |
US20120058056A1 (en) * | 2009-04-09 | 2012-03-08 | University Of Medicine And Dentistry Of New Jersey | Treatment of cutaneous hemangioma |
CN102908352A (zh) * | 2012-09-12 | 2013-02-06 | 北京英科博雅科技有限公司 | 特拉唑嗪或其盐在制备用于治疗败血症/脑卒中的药物中的用途 |
JP2014503591A (ja) * | 2011-01-26 | 2014-02-13 | ザフゲン,インコーポレイテッド | テトラゾール化合物ならびにその作製方法および使用方法 |
CN104189909A (zh) * | 2014-09-18 | 2014-12-10 | 中国人民解放军第三军医大学 | 肾上腺素受体拮抗剂在制备缓解脑损伤引起钠电流增加的药物中应用 |
-
2017
- 2017-09-15 JP JP2017177926A patent/JP2019052115A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60142922A (ja) * | 1983-12-28 | 1985-07-29 | Fujisawa Pharmaceut Co Ltd | 脳梗塞治療剤 |
JPH0256426A (ja) * | 1988-08-19 | 1990-02-26 | Sumitomo Pharmaceut Co Ltd | 虚血性脳障害処置剤 |
JP2005508922A (ja) * | 2001-10-04 | 2005-04-07 | ユーランド ファーマシューティカルズ リミテッド | プロプラノロールの時限徐放性多粒子剤型 |
WO2005030202A1 (en) * | 2003-09-26 | 2005-04-07 | Novartis Ag | Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders |
US20120058056A1 (en) * | 2009-04-09 | 2012-03-08 | University Of Medicine And Dentistry Of New Jersey | Treatment of cutaneous hemangioma |
JP2014503591A (ja) * | 2011-01-26 | 2014-02-13 | ザフゲン,インコーポレイテッド | テトラゾール化合物ならびにその作製方法および使用方法 |
CN102908352A (zh) * | 2012-09-12 | 2013-02-06 | 北京英科博雅科技有限公司 | 特拉唑嗪或其盐在制备用于治疗败血症/脑卒中的药物中的用途 |
CN104189909A (zh) * | 2014-09-18 | 2014-12-10 | 中国人民解放军第三军医大学 | 肾上腺素受体拮抗剂在制备缓解脑损伤引起钠电流增加的药物中应用 |
Non-Patent Citations (3)
Title |
---|
CEPHALALGIA (2013) VOL.33, NO.8(SUPPL.), P.255-256(P378), JPN6021023874, ISSN: 0004730859 * |
蘇生 (2007) VOL.26, NO.3, P.172-173(シンポジウム2(5)), JPN6021023872, ISSN: 0004730857 * |
診断と治療 (2016) VOL.104, NO.7, P.835-840, JPN6021023870, ISSN: 0004730858 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nonomura et al. | Piezo2 senses airway stretch and mediates lung inflation-induced apnoea | |
Vanni-Mercier et al. | Waking selective neurons in the posterior hypothalamus and their response to histamine H3-receptor ligands: an electrophysiological study in freely moving cats | |
Carli et al. | Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats | |
Eggermont | Pathophysiology of tinnitus | |
Soper et al. | Optogenetic activation of superior colliculus neurons suppresses seizures originating in diverse brain networks | |
Gao et al. | Activating an anterior nucleus gigantocellularis subpopulation triggers emergence from pharmacologically-induced coma in rodents | |
US20140241990A1 (en) | Methods of using adenosine a1 receptor activation for treating depression | |
KR20190131078A (ko) | Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물 | |
Yang et al. | Anesthetics fragment hippocampal network activity, alter spine dynamics, and affect memory consolidation | |
Micieli et al. | Single-unit analysis of the human posterior hypothalamus and red nucleus during deep brain stimulation for aggressivity | |
JP2022166055A (ja) | カリウムチャンネル開口薬としての有用な新規化合物 | |
Masvidal-Codina et al. | Characterization of optogenetically-induced cortical spreading depression in awake mice using graphene micro-transistor arrays | |
Manzoor et al. | Suppression of noise-induced hyperactivity in the dorsal cochlear nucleus following application of the cholinergic agonist, carbachol | |
US20220160688A1 (en) | Inhibition of nampt and/or sarm1 for the treatment of axonal degradation | |
Fernandez et al. | Cortical afferents onto the nucleus Reticularis thalami promote plasticity of low-threshold excitability through GluN2C-NMDARs | |
Gutierrez Herrera et al. | Neurons in the Nucleus papilio contribute to the control of eye movements during REM sleep | |
Chen et al. | Synchronized activity of sensory neurons initiates cortical synchrony in a model of neuropathic pain | |
Hérent et al. | Upregulation of breathing rate during running exercise by central locomotor circuits in mice | |
Maruo et al. | Laryngeal sensation and pharyngeal delay time after (chemo) radiotherapy | |
Torterolo et al. | Inferior colliculus unitary activity in wakefulness, sleep and under barbiturates | |
KR20200019747A (ko) | 순수한 5-ht6 수용체 길항제의 신규 용도 | |
JP2019052115A (ja) | 医薬組成物 | |
JP2019516696A (ja) | 純粋な5−ht6受容体アンタゴニストのnmda受容体アンタゴニストとの組合せ | |
KR20240024175A (ko) | 피부 신경섬유종의 치료에 사용하기 위한 니트록솔린 | |
ES2446296T3 (es) | Agente medicinal para el tratamiento de trastornos de la circulación cerebral o del flujo sanguíneo cerebral inducidos por beta amiloide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200731 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210622 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210810 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20211008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211021 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211011 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220322 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220920 |